Search clinical trials for: Sodium Mycophenolate

Total 10880 results

Eyestem Research Pvt. Ltd.

Not yet recruiting

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Geographic Atrophy | Retinal Disease
Zhishui Chen

Not yet recruiting

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Kidney Transplant Rejection
Massachusetts General Hospital
National Institute of Mental Health (NIMH); Institute for Medical Research,...

Recruiting

Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV (SOOTHE)

HIV | Major Depressive Disorder | Anxiety Depression

United States
University Hospital, Tours

Not yet recruiting

Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (INSTEAD)

Renal Transplant Rejection | Induction Therapy
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Renal Allograft Recipients

France, United States, Germany, Spain, United Kingdom, Italy, Netherlands, Belgium
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditions

United States
Fred Hutchinson Cancer Center
medac GmbH

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Anaplastic Large Cell Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States
National Institute of Allergy and Infectious Diseases...
PPD

Active, not recruiting

Tocilizumab in Cardiac Transplantation

Heart Transplant

United States
Novartis Pharmaceuticals

Active, not recruiting

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Lupus Nephritis

Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Adult Solid Neoplasm

United States
LI YAN

Completed

Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics

Kidney Transplant Patients

China
University of Miami
Novartis Pharmaceuticals

Completed

Myfortic vs. Cellcept in Kidney Transplant Recipients

End Stage Renal Disease

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

Lymphoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Hospital do Rim e Hipertensão

Completed

Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation (SEM)

Kidney Transplant Infection

Brazil
University of California, Los Angeles
Novartis

Completed

Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

Liver Transplantation

United States
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
Sanofi

Completed

A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant (START-DCD)

End-stage Renal Disease

China
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Rho Federal Systems Division, Inc.; Clinical Trials in...

Terminated

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Simultaneous Kidney and Pancreas Transplantation

United States
Poitiers University Hospital

Completed

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Chronic Kidney Disease

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

Kidney Transplantation

United States, United Kingdom, Germany, Belgium, Spain, Canada, Sweden
Cedars-Sinai Medical Center
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Heart Transplantation | Gastrointestinal Symptoms

United States
Novartis

Completed

Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Renal Transplantation | Gastrointestinal Problems

Germany, Switzerland
Medical University of South Carolina
Astellas Pharma Inc

Completed

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

Immunosuppression

United States
Stanford University

Completed

Allogeneic Transplantation From Related Haploidentical Donors

Leukemia | MDS | NHL | Graft Versus Host Disease | Blood Cancer | Malignancy | CLL | Hodgkin's Disease

United States
Stanford University
Genzyme, a Sanofi Company

Terminated

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Leukemia | Leukemia, Myeloid | Acute Myeloid Leukemia (AML)

United States
Augusta University

Unknown

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress (MMF)

Hypertension, Renal | Psychological Stress

United States
Ronaldo de Matos Esmeraldo, MD
Novartis Pharmaceuticals

Completed

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Cytomegalovirus Infections | Transplantation Infection

Brazil
Klemens Budde
Novartis Pharmaceuticals

Completed

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

Immunosuppression | Transplantation | Drug Interaction

Germany
Novartis Pharmaceuticals

Completed

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (MANDELA)

Heart Transplantation

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
Fibrolamellar Cancer Foundation

Withdrawn

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Hepatocellular Carcinoma | Hepatocellular Carcinoma (Fibrolamellar Variant)

United States
The University of Hong Kong

Completed

Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

Nephrosis, Lipoid

China
R. Mark Ghobrial, MD
Novartis

Completed

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

End Stage Liver Disease

United States
University of Pennsylvania
Novartis Pharmaceuticals

Terminated

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Transplants and Implants

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Myelodysplastic Syndromes | Leukemia

United States
National Institute of Allergy and Infectious Diseases...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Clinical...

Completed

Extended Follow-Up After Islet Transplantation in T1D

Type 1 Diabetes (T1D) | Islet Transplantation

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (Bu Flu TBI)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Myelodysplastic/Myeloproliferative Neoplasms

United States
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)

Kidney Maintenance Transplant
Helio Tedesco Silva Junior
Sanofi; Novartis

Completed

Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria

Kidney Transplantation | Cytomegalovirus

Brazil
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms

Renal Transplant

Korea, Republic of
Novartis Pharmaceuticals

Completed

Everolimus in de Novo Kidney Transplant Recipients (NEVERWOUND)

Kidney Transplantation

Italy
STZ eyetrial
Novartis Pharmaceuticals; University Hospital Tuebingen

Completed

Myfortic for the Treatment of Non-infectious Intermediate Uveitis (MYCUV-IIT02)

Uveitis, Intermediate

Germany
Novartis Pharmaceuticals

Completed

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (ATHENA)

Kidney Transplantation | Renal Transplantation

Germany, France
Novartis Pharmaceuticals

Completed

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Renal Transplant

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

France
Asan Medical Center
Samsung Medical Center; Seoul National University Hospital

Completed

Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients (OPTIMUM)

Kidney Transplantation

Korea, Republic of
Novartis Pharmaceuticals

Withdrawn

Observational Registry Study of Renal Transplant Patients (MORE registry)

Kidney Transplant

United States
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients

Kidney Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients

Kidney Transplant

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS

Search clinical trials for: Sodium Mycophenolate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations